Post-earnings recap
Reported
Wed, Apr 29, 2026
EPS actual
$-0.18
EPS est.
$-0.30
EPS surprise
+39.60%
1-day move
-2.23%
Glaukos Corporation reported a smaller loss than analysts expected, which is a positive sign for the company. However, the stock still declined by 2.23% following the earnings report, indicating that investors may have been looking for more positive news or clearer guidance. The lack of revenue information and management commentary may have contributed to the stock's downward movement.
| Metric | Actual | Expected | Surprise |
|---|---|---|---|
| EPS | $-0.18 | $-0.28 | +39.60% |
| Revenue | N/A | $137M | N/A |
No transcript is on record, and the analysis is based on numerical results only.
Glaukos Corporation is a healthcare company focused on developing innovative products for the treatment of eye diseases, particularly glaucoma. With a market cap of $7 billion, it plays a crucial role in the health care equipment sector, addressing a growing need for effective eye care solutions.
Last quarter
In Q4 2025, Glaukos reported an EPS of -$0.28, missing expectations. The stock reacted negatively, dropping 2.59% the following day.
EPS beat streak
2Q
EPS beat rate
88%
Avg EPS surprise
+24.40%
Avg 1-day reaction
-0.05%
Analysts expect Glaukos to report a loss of $0.28 per share on revenues of $137 million. Investors are watching closely for any signs of improved sales or cost management.
Bull case
If Glaukos can exceed revenue expectations and show a narrower loss, it could signal a turnaround in its financial performance, boosting investor confidence.
Bear case
Conversely, if the company fails to meet revenue targets or reports a wider loss, it may raise concerns about its growth prospects and operational efficiency.
Key metrics to watch
EPS
-$0.28Earnings per share is a key indicator of profitability and will show how well the company is managing its costs.
Revenue
$137MRevenue figures will provide insight into the company's sales performance and market demand for its products.
The print will turn on these.
Q1
Will Glaukos achieve revenue of at least $137 million this quarter?
Meeting or exceeding this revenue target is crucial for demonstrating demand for their products and could influence investor sentiment.
Q2
How will the company address its ongoing losses?
Investors will be keen to hear management's strategy for improving profitability, which is critical for long-term growth.
—
Est. EPS
$1.52
Est. Rev
$3.6B
Impl. Move
±39.2%
Why consensus could be wrong
The consensus may underestimate Glaukos' potential for revenue growth due to recent product launches that could drive sales higher than expected.
Supporting evidence
The company has a strong history of beating EPS estimates, with a 75% success rate in the last eight quarters.
Options pricing suggests a significant move, indicating that traders are anticipating a more volatile response than historical averages.
Recent insider selling may not reflect a lack of confidence but rather strategic financial management.
Key risk
If revenue exceeds $143 million, it could challenge the current bearish sentiment.
Pre-commit to what would confirm each case.
This quarter's performance is pivotal as it will reflect the company's ability to rebound from recent losses and improve its market position.
Bull confirmed if
Revenue exceeding $137 million with a narrower EPS loss than -$0.28 would confirm the bull case.
Bear confirmed if
An EPS loss greater than -$0.28 alongside revenue below $130 million would confirm the bear case.
What the market is pricing for the move.
Implied Move
±12.55%
Historical Avg
±2.0%
The options market is pricing in a significant move, suggesting traders expect volatility around the earnings report.
Options are pricing ±12.5% while GKOS has averaged ±2.0% over the last 8 prints — setup is pricing rich.
ATM IV
0.8%
30d HV
38.2%
Open-market trades by officers, directors, and 10%+ holders over the trailing 90 days.
Bought
$0.00
0 sh
0 insiders
Sold
$500,278.56
3,142 sh
1 insider
Net
$500,278.56
Net selling
Most Active Insiders· 7 open-market trades
$500,278.56
Net selling
Smart-money positioning from the most recent 13F filings.
Institutional
105.30%
of float
Insider
3.58%
of float
Holders
498
institutions
Top Holders· as of Jun 2026
Blackrock Inc.
9,540,056 sh · $1.6B
16.17%
5.0%
Likely market behavior by outcome. Not investment advice.
Beat & raise
If Glaukos beats expectations, history suggests the stock could rise by around 0.22% on average, confirming a positive outlook.
In line / cautious
Should results come in line with expectations, the stock may react cautiously, reflecting uncertainty in management's future guidance.
Miss
If the company misses expectations, history suggests a potential decline of about 0.22%, indicating investor disappointment.
The lines on the call that would change the story.
Recent Transactions
Sep 25, 2026 · @ $154.88
1,083 sh
$167,735.04
Oct 5, 2026 · @ $163.93
888 sh
$145,569.84
Oct 5, 2026 · @ $164.78
327 sh
$53,883.06
Oct 5, 2026 · @ $165.60
312 sh
$51,667.20
Sep 25, 2026 · @ $154.24
229 sh
$35,320.96
Open-market trades only (Form 4 codes P/S). Awards, exercises, and tax-withholding excluded as routine compensation noise.
Jupiter Topco LLC
4,862,894 sh · $837.3M
8.24%
100.0%
Vanguard Portfolio Management LLC
3,321,839 sh · $572.0M
5.63%
3.5%
Primecap Management Company
3,040,705 sh · $523.5M
5.16%
-9.8%
Vanguard Capital Management LLC
2,551,132 sh · $439.3M
4.33%
1.7%
13F filings updated quarterly. Position deltas show change in shares vs. the prior quarter.